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Abstract
BACKGROUND: FADS1 gene encodes delta 5 desaturase, a rate-limiting enzyme in the 
metabolism of n-3 and n-6 polyunsaturated fatty acids (PUFAs). Minor alleles of FADS1 locus 
polymorphisms are associated with reduced FADS1 expression and intra-hepatic fat accumulation. 
However, the relationship between FADS1 expression and pediatric nonalcoholic fatty liver 
disease (NAFLD) risk remains to be explored.
METHODS: We analyzed FADS1 transcription levels and their association with intra-hepatic fat 
and histology in children, and we performed pathway enrichment analysis on transcriptomic 
profiles associated with FADS1 polymorphisms. We also evaluated the weight of FADS1 alleles 
on the response to combined docosahexaenoic acid, choline, and vitamin E (DHA-CHO-VE) 
treatment.
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RESULTS: FADS1 mRNA level was significantly and inversely associated with intra-hepatic fat 
(p = 0.004), degree of steatosis (p = 0.03), fibrosis (p = 0.05), and NASH (p = 0.008) among 
pediatric livers. Transcriptomics demonstrated a significant enrichment of a number of pathways 
strongly related to NAFLD (e.g., liver damage, fibrosis, and hepatic stellate cell activation). 
Compared to children who are common allele homozygotes, children with FADS1 minor alleles 
had a greater reduction in steatosis, fibrosis, and NAFLD activity score after DHA-CHO-VE.
CONCLUSION: This study suggests that decreased FADS1 expression may be associated with 
NAFLD in children but an increased response to DHA-CHO-VE.
INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in 
children but its pathogenesis remains incompletely understood. The prevalence of pediatric 
NAFLD in the U.S. was estimated to be 8–17% but up to 38% among obese children.1 
NAFLD is defined as a spectrum of chronic liver disorders, beginning as an accumulation of 
fat in the liver without significant alcohol consumption that can gradually progress to 
steatohepatitis (nonalcoholic steatohepatitis (NASH)) and even cirrhosis in children, leading 
to substantial liver injury.2,3 Also, NAFLD in children is highly associated with a series of 
early metabolic conditions, including obesity, insulin resistance, glucose intolerance, and 
cardiovascular abnormalities,4 exerting an enormous medical challenge for pediatric care.5 
Understanding the etiology of pediatric NAFLD and NASH is poor especially when 
compared to extensive studies in adults.1,5 Given the current rapid growing population of 
NAFLD and its co-morbidities in children, it is an urgent need to elucidate the principle 
disease etiology and develop safe and effective treatment for pediatric NAFLD.
It is well recognized that n-3 polyunsaturated fatty acid (PUFA) deficiency is associated with 
many metabolic perturbations, including NAFLD.6–9 In humans, particularly due to the high 
n-6/n-3 PUFA ratio in Western diet, n-3 PUFA deficiency has been associated with NAFLD 
and NASH in both adults and children.10–19 Small clinical studies in children suggest that 
n-3 PUFA supplementation may improve NAFLD.20 However, recent large clinical trials of 
n-3 PUFA in adults with NAFLD have yielded mixed results.21–24 While inter-individual 
variability has been recognized as a key factor influencing the response to n-3 PUFA 
treatment,25–27 the clinical trials testing the effectiveness of n-3 PUFA in NAFLD have not 
considered genetic variability in n-3 PUFA metabolism among study participants.
Both n-6 and n-3 PUFA metabolism are controlled by Δ5 and Δ6 desaturases (D5D, D6D) 
encoded by FADS1 and FADS2 genes, respectively. D5D is the rate-limiting enzyme in 
converting α-linolenic acid, the major dietary n-3 PUFA precursor, into the bioactive forms 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Our recent studies indicated 
that FADS1 is significantly involved in hepatic fat accumulation and NAFLD.28,29 Notably, 
among the genes involved in this pathway, FADS1 harbors genetic alleles in strong linkage 
disequilibrium (LD; allele frequency ranging from 32% to 43%30 consistently identified as 
the most important determinants for FADS1 (i.e., D5D) activity and endogenous n-3 PUFA 
levels in humans.30–32 In addition, increasing evidence suggests that FADS1 low-function 
alleles can influence both the pharmacokinetics and pharmacodynamics of supplemented n-3 
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PUFA, potentially leading to inter-patient differences in response to its intake.26,27 
Unfortunately, no clinical study thus far has considered these alleles in testing the 
effectiveness of n-3 PUFA in treating NAFLD. Further delineating this pharmacogenetic 
mechanism may lead to a more effective n-3 PUFA treatment for NAFLD.
In this proof-of-concept study, we evaluated the relationship between FADS1 expression and 
liver histology in pediatric liver samples and explored the molecular pathway associated 
with low-function FADS1 alleles. Further, we examined the relationship between FADS1 
polymorphism and clinical response to DHA supplementation combined with choline and 
vitamin E (DHA-CHO-VE) in a small cohort of children with NAFLD who have completed 
a randomized clinical trial registered33 at ClinicalTrials.gov (ID: NCT01934777).
METHODS AND MATERIALS
Samples
Samples used in this study as well as the data analysis plan using the samples are reported in 
Fig. 1.
The liver tissue samples were described previously.28 Briefly, these are leftover tissue 
samples collected from liver transplantation donors who are deceased individuals but were 
willing to donate their organs for transplantation purposes. Demographic information of the 
donors was demonstrated in Table 1. Transcriptomic data from 55 pediatric liver tissue 
samples (aged 0–18years) were collected previously, among which only 22 were 
characterized for histologic evaluation. Genotypic data of 6 FADS1 single-nucleotide 
polymorphisms (SNPs;rs174576, rs1535, rs174546, rs102275, rs174537, and rs174556) for 
all 55 pediatric liver samples were previously collected.28
Total hepatic fat content was measured using a protocol established in our previous study.34 
The degree of steatosis was visually assessed based on the hematoxylin–eosin–stained tissue 
sections and the total collagen content was quantified by Sirius red staining. The presence of 
NAFLD and NASH was defined based on the previously established method by NASH-
CRN.35
Study population from clinical trial
Nineteen children with NAFLD belonging to the treatment arm of DHA-CHO-VE trial were 
included in the study. In particular, these children presented a liver biopsy-proven diagnosis 
of NASH. Other causes of liver diseases were excluded before the enrollment in the trial. 
These included: the presence of liver disease due to any of the following: Wilson disease, 
hepatitis B and C, acute systemic disease, autoimmune hepatitis, hypothyroidism, cystic 
fibrosis, celiac disease, and suspicion of muscular dystrophy, alpha-1-antitrypsin deficiency, 
and metabolic inherited diseases. Patients were also excluded if body weight and 
carbohydrate metabolism were altered by the use of parenteral nutrition, protein 
malnutrition, previous gastrointestinal surgery, structural abnormalities of the 
gastrointestinal tract, or neurological impairment. Finally, the use of nonsteroidal anti-
inflammatory drugs, antibiotics, probiotics, or antisecretory drugs capable of causing 
achlorhydria within the 2 months preceding enrolment were considered additional exclusion 
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criteria. Details of the trial have been already reported.33 However, briefly, all children in the 
treatment arm received, every day for 6 months, pearls combining 250 mg of DHA, 39 UI of 
vitamin E, and 201 mg of choline (DHA-CHO-VE). Pearls were provided by DMF Dietetic 
Metabolic food (Italy). Concomitantly, all patients received recommendation for hypocaloric 
diet (25–30 kcal/kg/day) and twice weekly 1-h physical activity during the treatment and for 
further 6 months of follow-up. Compliance to treatments and diet was monitored through 
monthly visit by counting the amount of investigational product left in the bottle.
Symptoms and side effects were assessed in each visit by the investigator, who was blind to 
medication assignment. Complete medical histories were recorded for all participants. 
Collection of anthropometrical data, biochemical data, and second biopsy were performed at 
baseline and after 12 months from trial start. Patients and investigators were blinded before 
and after the assignment of the intervention. The study was registered at ClinicalTrials.gov, 
with the number ID: NCT01934777 on 30 August 2013. However, we underline that the 
current primary end point differs from the original protocol submitted to ClinicalTrials.gov 
as well as described in the previous study.33 The Bambino Gesù Ethics Research Committee 
approved the study, in accordance with the Declaration of Helsinki, and parents of the 
included patients gave their written informed consent to therapies and the tests performed 
for research purpose.
Anthropometrics
Anthropometric data were collected at baseline and after 12 months. Weight was measured 
by a conventional scale with a precision of 100 g and height was measured by a Harpenden 
stadiometer with a precision of 1 mm. Body mass index was expressed in kilograms per 
square meters (kg/m2).
Laboratory parameters
Blood were collected at baseline and at month 12 after an overnight fasting and immediately 
processed to perform the analysis of alanine aminotransferase, aspartate aminotransferase, 
gamma-glutamyl-transferase, total triglycerides and cholesterol, high-density lipoprotein, 
low-density lipoprotein, glucose, and uric acid by standard laboratory methods. 
Demographic information of the donor individuals are reported in Table 3.
Genotyping
Genotyping of 17 SNPs (rs174545, rs174546, rs174547, rs174548, rs174549, rs174550, 
rs174555, rs174556, rs174560, rs174561, rs174562, rs174568, rs1535, rs174574, rs174576, 
rs174577, and rs174581) across the FADS locus in the NAFLD children treated with DHA-
CHO-VE were performed using with Sequenom MassARRAY iPLEX Gold assays 
(Sequenom, San Diego, CA). However, given the high LD level among these 17 FADS SNPs 
(pairwise LD r2 > 0.8), we chose the FADS variant rs174576 as a representative SNP for all 
subsequent analyses. We chose this SNP also because it was associated with fatty acid 
denaturation pathway activity, whole-body fat oxidation, and DHA/EPA index in young 
individuals.36,37
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Statistical analyses
The association between six FADS1 SNPs and transcriptome data of donor liver tissues (n = 
55) was performed using R package Matrix eQTL.38 Each SNP in FADS1 region was 
assessed for the association with liver transcriptome using multiple linear regression model, 
where age, gender, and ancestry were adjusted for the association as covariates. The SNP 
was coded using dominant genetic model, i.e., AA: 0, AB and BB: 1. We selected genes 
significantly (p < 0.05) associated with all the six FADS1 SNPs for pathway analysis. Note 
that, given the small sample size, we used a liberal nominal p value (0.05) as a statistical 
significance cutoff for selecting genes for the pathway analysis so that critical pathways may 
not be missed. Significantly (p <0.05) enriched pathways were identified using Ingenuity 
Pathway Analysis (IPA®, QIAGEN, Redwood City, www.qiagen.com/ingenuity).
Demographic, biochemical, and histological features of the NAFLD children (n = 19) were 
compared between groups using Wilcoxon rank-sum test for continuous variables. Multiple 
logistic regression model was used to test the association between FADS1 genotype and the 
response to the treatment in terms of steatosis reduction. Genotypes were coded in dominant 
genetic model. Age, gender, and the genotypes of PNPLA3 (rs738409)39 and TM6SF2 
(rs58542926)40 were adjusted for the association. Logistic regression was performed using 
the package PLINK 1.07.41 All the other analyses were performed using R statistical 
packages (www.r-project.org).
RESULTS
Association between FADS1 mRNA and liver histology in children We have characterized 
biochemical, and histologic features of donor liver tissue samples of 22 children. As 
summarized in Table 1, we found that 4 out of 22 individuals possess a ≥5% steatosis in 
their livers, and all these 4 patients were characterized as NASH or borderline NASH. The 
total fat content of all 22 livers is 0.02 ± 0.0088 mg fat per mg tissue, and total collagen 
content is 8.2 ± 4.4%.
We aimed to understand the relationship between FADS1 transcription and liver histology in 
children. We found that FADS1 mRNA level was significantly and inversely associated with 
total hepatic fat content (p = 0.004), degree of steatosis (p = 0.03), fibrosis (p = 0.05), and 
NASH (p = 0.008) among pediatric livers (Fig. 2).
Pathway enrichment of genes associated with FADS1 polymorphism
Our previous study has demonstrated that the minor alleles of FADS1 variants are associated 
with decreased hepatic FADS1 transcription.28 We hypothesized that these FADS1 low-
function alleles may lead to an altered transcriptomic profile where certain pathways 
involved in nonalcoholic fatty liver disease may be affected. In order to test this hypothesis, 
we performed a genome-wide analyses on the association between FADS1 variant genotypes 
and mRNA expression. At a nominal significance level (p < 0.05), we identified 619 genes 
whose mRNA expression is significantly associated with FADS1 genotype (Supplemental 
Table S1 (online)). We further conducted a pathway enrichment analysis on these genes 
using the IPA package. Our analysis revealed a significant enrichment for a number of 
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pathways strongly related to NAFLD: hepatic fibrosis/hepatic stellate cell Activation) (p = 
0.01), protein kinase A signaling (p = 0.01), and VDR/RXR activation (p = 0.002) as well as 
multiple interleukin signaling pathways (p < 0.05) (Supplemental Table S2 (online)). Given 
the association between the minor alleles of FADS1 variants and the low FADS1 expression 
and function, we sought to explore whether the liver transcriptome profile associated with 
these minor alleles is also more likely associated with NAFLD. We then performed IPA 
toxicity function pathway analysis specifically for the genes whose expression is positively 
associated with the FADS1 minor alleles. As demonstrated in Table 2, critical toxicity 
function pathways, e.g., activation of liver fibrosis (p = 0.01), hepatic fibrosis (p = 0.014), 
and liver damage (p = 0.02), are particularly enriched. Also, hepatic fibrosis (p = 0.006) and 
increased liver damage (p = 0.044) are also top pathways significantly enriched among the 
toxicity Lists. Again, triacylglycerol biosynthesis (p = 0.046) and hepatic fibrosis/hepatic 
stellate cell activation (p = 0.047) are significantly enriched top canonical pathways (Table 
2).
Association between FADS1 alleles and clinical response to n-3 lipid supplementation in 
children
We postulated that, while the low-function FADS1 alleles may increase the susceptibility to 
NAFLD, supplementation n-3 lipids to NAFLD patients would lead to a better response in 
improving the liver histology. We therefore genotyped the FADS1 variants among NAFLD 
children who previously received DHA-CHO-VE treatment. Given the high LD level among 
these variants in the study cohort (r2 > 0.8), we selected rs174576 as a representative variant 
for the analyses. We then assessed the association between rs174576 minor allele and the 
improvement in liver histology after the DHA-CHO-VE treatment. We found that, as 
compared to the carriers of the major allele homozygotes, the minor allele carriers 
(heterozygotes and minor allele homozygotes) possessed a significant reduction in steatosis, 
fibrosis, ballooning, and NAFLD activity score (p < 0.02 for all tests;Table 3). As other 
NAFLD-associated genetic variants, i.e., PNPLA3 and TM6SF2, may confound this 
association,39,40 we further performed a multivariate analysis using a linear regression 
model by incorporating the genotype of these two genes. We found that the rs174576 minor 
allele remained to be significantly (p < 0.05) associated with more steatosis reduction after 
the DHA-CHO-VE treatment (Supplemental Table S3 (online)).
DISCUSSION
Our study demonstrated that reduced hepatic FADS1 transcription is associated with 
increased risk to NAFLD in children. The low-function alleles of FADS1 are particularly 
associated with alteration of molecular pathways involved in NAFLD. In addition, children 
with NAFLD who are carriers of FADS1 low-function alleles are the best responders to n-3 
lipid supplementation. Our findings together indicate an important role of FADS1 function 
in the pathogenesis of NAFLD in children. Moreover, FADS1 genetic variants may be a 
useful pharmacogenetic marker capable of distinguishing the patients who are more likely to 
respond to n-3 lipid supplementation as a therapeutic strategy for NAFLD/NASH in 
children.
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Our results provide new evidence supporting the association between the insufficiency of 
n-3 PUFA and NAFLD/NASH. While this association may be largely attributed to the 
imbalanced n-3/n-6 PUFA in the current Western diet, certain genetic perturbations of fatty 
acid desaturation process may exacerbate this issue. As compared to extensive dietary 
research, the relationship between genetic variability in fatty acid desaturation and NAFLD/
NASH was less clear. This issue could be crucial in pediatric NAFLD since genetic factors 
may play a more significant role in disease susceptibility at the earlier stage of human 
development, as compared to the dietary and other environmental factors. Our previous 
studies have revealed that minor alleles of multiple variants across the FADS1 locus lead to 
reduced hepatic transcription level of FADS1, which is further associated with reduced 
desaturation flux of long chain fatty acids but increased total intra-hepatic fat accumulation 
and susceptibility to liver steatosis.28,29 Accordingly, our current study demonstrated that 
reduced FADS1 function in the liver is highly correlated with not only increased steatosis 
but also with fibrosis and NASH. This correlation may be mediated by the altered molecular 
pathways involved in lipid homeostasis, as well as in hepatic fibrogenesis, suggesting that 
insufficient FADS1 function can lead to both molecular and pathological changes in the liver 
even at the early developmental stages of the disease. Besides the central function of FADS1 
in the liver, the gut–liver axis derangement may also be involved in the lipid homeostasis in 
the liver.42 Gut microbiota was found to produce PUFA43; our recent study demonstrated 
that FADS1 genotype may also influence the oxidized derivatives of linoleic acid that are 
associated with metabolic syndrome and adverse lipid protein profiles in children.44 It is 
thus possible that FADS1 alleles play a role in multiple systems in increasing the 
susceptibility to NAFLD.
Our findings also have implications in clinical management of NAFLD in children. Given 
the increased understanding of the key role of n-3 PUFA in NAFLD, supplementation of n-3 
PUFA to NAFLD patients has long been a potential treatment and preventive option for 
NAFLD/NASH. Our study revealed a potential mechanism that leads to inter-patient 
variability in response to n-3 PUFA intake. Our findings suggest that FADS1 variants can be 
a pharmacogenetic marker that is useful for selecting NAFLD patients who are most likely 
to respond to n-3 PUFA supplementation. Our study is consistent with previous studies 
where FADS1 minor alleles are associated with significantly better tissue accumulation of 
n-3 PUFA after supplementation.26,27 This hypothesis is also supported by the recent large 
cohort study on using n-3 PUFA supplementation in pregnant women to prevent asthma in 
their children where carrying FADS1 minor alleles in the pregnant women was found to be 
predictive of better response in their children.45 As a particular biomarker for n-3 PUFA 
treatment for NAFLD has not been established, our study warranted further validation of the 
potential predictive value of FADS1 variants in the treatment or prevention of NAFLD in 
children and beyond, in particular via prospective clinical studies.
Our study was limited in several aspects. First, the small sample size leads to a low power in 
testing the relationship between FADS1 alleles, gene expression, and NAFLD histology or 
drug responses in our sample sets. A post hoc power calculation indicated that the majority 
of our tests is potentially under-powered (data not shown). Therefore, our findings should be 
limited to the observations in our cohorts and the result should be further validated in larger-
scale sample sets. However, we have previously reported a strong association between 
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FADS1 minor alleles and decreased hepatic FADS1 gene expression, whereas increased total 
liver fat content.28 Therefore, the findings in this study indeed validated at least in part our 
previous observations. Moreover, noteworthy, in our study the consistent association 
between FADS1 and clinical features as well as drug responses, albeit weak, collectively 
generated a new interesting hypothesis worth further testing in the future. Second, the age 
group of the donor cohort (6.1 ± 4.4 years) is different from that of the clinical study (13.00 
± 2.45 years). Therefore, the biological effect observed in the former population may not 
reflect that of the latter. Third, the NAFLD patients in our study were treated with a 
combined choline, DHA, and VE rather than n-3 PUFA as a single agent. The result thus 
could be confounded by the pharmacological effects of other compounds. It is thus 
necessary to design prospective clinical studies in a large population to specifically 
investigate the relationship between FADS1 alleles and clinical outcomes of n-3 PUFA 
supplementation. Nevertheless, our study generated interesting directions and hypotheses for 
understanding the pathogenesis and developing therapeutic/preventive strategies for pediatric 
NAFLD.
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Fig. 1. 
Diagram of sample sets used in this study as well as the data analysis plan
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Fig. 2. 
Correlation between FADS1 mRNA level and total fat content (a), steatosis level (b), 
fibrosis level (c), and NASH status (d)
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Table 1.
Biochemical and histological characteristics of the donor liver tissue samples (n = 22)
Male sex, n (%) 12 (54.5)
Age (years)
Mean ± SD 6.1 ± 4.4
 Median (IQR) 4.5 (2.25–9)
BMI (kg/m2)
Mean ± SDa 17.7 ± 5.9
 Median (IQR) 16.5 (15.5–17.6)
Race
 White 17 (77.3)
 Black 5 (22.7)
Biochemical features
 Sirius red, mean ± SD (%) 8.2 ± 4.4
Histological features
 Total hepatic fat, mean ± SD (mg fat/mg tissue) 0.020 ± 0.0088
 Steatosis (%, >5%) 4 (18.2)
 NASH 4 (18.2)
The quantification of Sirius red staining is based on the percentage of the stained area of the liver tissue section
aSD standard deviation, BMI body mass index, IQR interquartile range Missing information for six participants.
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